Axol Bioscience

Axol Bioscience is a leading provider of human iPSC-derived cells and contract services, operating as a critical enabler for drug discovery in human disease modeling. With over a decade of expertise, the company manufactures functional cells like cardiomyocytes and neurons and offers services including custom cell production, disease model creation, reprogramming, and gene editing. It holds ISO 9001:2015 certification for manufacturing and serves a global clientele, positioning itself at the intersection of the growing iPSC tools and services market. The company is privately held and appears to be in a revenue-generating stage, supported by its portfolio of products and collaborative projects.

Proprietary platform for manufacturing high-quality, functionally validated human iPSC-derived cells (e.g., neurons, cardiomyocytes, retinal cells). Includes an iPSC line library, optimized differentiation protocols, gene editing (CRISPR) capabilities, and scale-up manufacturing processes certified to ISO 9001:2015. Also developing advanced assay-ready disease models (e.g., high-throughput Dry-AMD model).

Axol competes in the crowded iPSC tools and services market. Key competitors include established players like Fujifilm Cellular Dynamics International (CDI) and Thermo Fisher Scientific, as well as numerous specialized startups (e.g., Neurix, BrainXell in neuroscience). Differentiation is achieved through deep expertise in specific disease areas (notably ALS), focus on functional QC, ISO-certified manufacturing, and a strong service-oriented, collaborative business model.